Aelin Therapeutics, founded in 2017, is a pioneering Belgian biotherapeutics company emerging from the collaborative efforts of VIB and partner universities KU Leuven, VUB, and UGent. Known for its slogan "Empowering innovative biotherapeutic designs that target bacteria, cancer cells, fungi, viruses, and plant cells with unmatched precision," the company is built on groundbreaking research by structural biologists Prof Joost Schymkowitz and Prof Frederic Rousseau.
Aelin Therapeutics has carved a niche in the Biotechnology and Health Care sectors, notably through its proprietary Pept-in technology. This technology provides a unique mode of action, allowing for the rational design and targeting of intracellular spaces that have been unreachable by traditional methodologies. The company has received recognition through publications in high-impact journals such as Science.
In its Series A round on 11 December 2017, the company secured a significant investment of €27.00M from top-tier investors including Novartis Venture Fund, Fund+, PMV, LSP BioVentures, and Boehringer Ingelheim Venture Fund, showcasing strong market confidence in its innovative approach.
